At a glance
- Originator Abbott GmbH & Co. KG
- Developer Abbott GmbH & Co. KG; Grunenthal; Pharma Bio-Research International; University of Ulm
- Class Cardiac glycosides; Heart failure therapies
- Mechanism of Action Adenosine triphosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute heart failure
Most Recent Events
- 31 May 2001 Discontinued-Preclinical for Heart failure in Germany (IV)
- 31 May 2001 Discontinued-Preclinical for Heart failure in Netherlands (IV)
- 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories